Acetyl-APEX1 (K6) Antibody

What is APEX1 and what is the significance of its acetylation at K6?

APEX1 (also known as APE, APE1, APEX, HAP1, or REF1) is a multifunctional protein that serves as a DNA-(apurinic or apyrimidinic site) lyase and redox factor-1 (REF-1) . APEX1 can be post-translationally modified via acetylation on several critical lysine residues, including K6, K7, K27, K31, K32, and K35 .

Acetylation at these residues, particularly K6, plays crucial roles in several aspects of APEX1 function:

• Prevention of proteolysis and enhancement of activity

• Promotion of nuclear distribution and DNA binding

• Regulation of protein stability under diverse stimuli

• Modulation of interactions with protein partners like rRNA and NPM1

Acetylation of APEX1 is a mechanistically important modification that affects its cellular localization, with acetylated APEX1 showing predominant nuclear accumulation in various cell types .

What are the specifications and applications of Acetyl-APEX1 (K6) Antibody?

The Acetyl-APEX1 (K6) Antibody is a rabbit polyclonal antibody specifically designed to detect endogenous levels of APEX1 protein acetylated at lysine 6 . The antibody specifications and recommended applications include:

The antibody specifically detects acetylated APEX1 without cross-reactivity to the non-acetylated form, making it valuable for studying changes in APEX1 acetylation status under various experimental conditions .

How should researchers validate the specificity of Acetyl-APEX1 (K6) Antibody?

Validating antibody specificity is critical for accurate interpretation of experimental results. For Acetyl-APEX1 (K6) Antibody, consider these validation approaches:

• Positive controls: Treat cells with deacetylase inhibitors like trichostatin A (TSA) to increase acetylation levels of APEX1 . This should result in increased signal detection by the antibody in Western blotting and immunofluorescence experiments.

• Binding affinity assessment: If developing or characterizing new antibodies against acetylated APEX1, determine binding constants through dose-response curves. High-affinity antibodies typically show KD values in the picomolar range (280-760 pM) for acetylated peptides .

• Comparative analysis: Use parallel samples with a pan-APEX1 antibody to compare total protein levels versus acetylated protein .

• Peptide competition assays: Pre-incubate the antibody with acetylated and non-acetylated peptides to confirm specificity for the acetylated form .

• Knockout/knockdown validation: Use APEX1-depleted cells as negative controls to confirm the absence of signal .

How can researchers use Acetyl-APEX1 (K6) Antibody to study endothelial cell function in atherosclerosis?

APEX1 has been implicated in vascular endothelial cell (EC) function and atherosclerosis development. The Acetyl-APEX1 (K6) Antibody can be utilized to investigate:

• Flow-dependent APEX1 acetylation: Different flow patterns (oscillatory shear vs. protective steady flow) differentially affect APEX1 acetylation in endothelial cells . Use the antibody to compare acetylation levels between cells exposed to different shear patterns in flow chamber systems.

• APEX1 role in inflammatory responses: Acetylated APEX1 mediates pro-inflammatory responses in endothelial cells. The antibody can detect changes in APEX1 acetylation following treatment with inflammatory cytokines like TNF-α .

• Effects of potential therapeutics: Compounds like vitexin inhibit APEX1 acetylation and nuclear translocation. The antibody can assess changes in acetylation levels following treatment with these compounds .

• Mechanistic studies of secreted APEX1: Acetylated APEX1 can be secreted by endothelial cells and modulate TNF-α-mediated inflammation. The antibody can detect extracellular acetylated APEX1 in culture medium or tissue sections .

Researchers found that endothelial Apex1 contributes to disturbed flow-accelerated atherogenesis, and depletion of endothelial Apex1 in mice ameliorated atherogenesis, suggesting a potential therapeutic target .

What mechanisms regulate APEX1 acetylation and nuclear translocation?

APEX1 nuclear translocation is regulated by its acetylation status, which can be studied using the Acetyl-APEX1 (K6) Antibody in several experimental approaches:

• Acetyltransferase involvement: APEX1 acetylation is likely mediated by the acetyltransferase p300. Oscillatory shear (OS) and TNF-α induce nuclear translocation of APEX1 by enhancing the binding of p300 to APEX1, leading to increased acetylation .

• Shear-regulated modifications: Distinct shear patterns differentially affect p300 phosphorylation and its binding to APEX1 in endothelial cells. OS elevates p300 phosphorylation and promotes its binding to APEX1 .

• Deacetylation dynamics: The interaction between APEX1 and HDAC1 (histone deacetylase 1) facilitates the recruitment of HDAC1 to the promoter regions of APEX1-targeted genes, potentially regulating transcriptional activity .

• Subcellular fractionation analysis: To study nuclear translocation, researchers can use Acetyl-APEX1 (K6) Antibody in immunoblotting of nuclear and cytoplasmic fractions of cells treated with acetylation modulators .

Experimentally, treating endothelial cells in protective steady state (PS) condition with deacetylase inhibitors increases nuclear accumulation of APEX1, mimicking the effect of oscillatory shear (OS) .

What methodological approaches can be used to quantify APEX1 acetylation in cellular and tissue samples?

Quantifying APEX1 acetylation levels is essential for understanding its regulation in different physiological and pathological conditions. Several methodological approaches can be employed:

• Western blotting with Acetyl-APEX1 (K6) Antibody:

  • Treat cells with deacetylase inhibitors (e.g., TSA) to induce hyperacetylation

  • Prepare total cell extracts or subcellular fractions

  • Detect acetylated APEX1 using the specific antibody

  • Compare to total APEX1 levels using a pan-APEX1 antibody

• Immunoprecipitation followed by acetylation detection:

  • Precipitate APEX1 from cell lysates

  • Detect acetylated lysine residues in the immunocomplexes using anti-acetylated-lysine antibodies

  • This approach revealed higher enrichment of acetylated lysine residues in APEX1 under oscillatory shear compared to protective steady flow

• Proximity Ligation Assay (PLA):

  • Use a commercial antibody recognizing the N-terminus of APEX1 in combination with Acetyl-APEX1 (K6) Antibody

  • This technique evaluates the physical proximity (<40 nm) between two epitopes

  • Ideal for mapping post-translational modifications in specific amino acid regions

  • Shows increased positive signals in cells treated with deacetylase inhibitors

• Immunofluorescence microscopy:

  • Monitor subcellular localization of acetylated APEX1

  • Quantify the proportion of cells showing nuclear, cytoplasmic, or pancellular distribution patterns

  • Analyze colocalization with other proteins of interest

How can researchers study the interaction between vitexin and APEX1 acetylation?

Vitexin, a natural flavonoid, inhibits APEX1 acetylation and subsequent nuclear translocation. To study this interaction and its effects, researchers can employ these approaches:

• Cellular Thermal Shift Assay (CETSA):

  • This assay monitors drug-target engagement based on ligand-induced thermal stabilization

  • Treat cell lysates or intact cells with vitexin or DMSO control

  • Heat samples to 50-60°C

  • Analyze soluble fractions by Western blotting to quantify APEX1

  • Vitexin treatment showed thermal stabilization of APEX1 with thermal shifts of 2°C (intact cells) and 4°C (cell lysates), indicating target engagement

• Surface Plasmon Resonance (SPR):

  • Use this technique to identify kinetic parameters of molecular interactions in real-time

  • Immobilize recombinant APEX1 protein

  • Measure resonance units upon addition of increasing vitexin concentrations

  • Calculate equilibrium dissociation constant (KD)

  • Vitexin interacted with APEX1 with a KD of 2.344 × 10−5 mol/L, while E3330 (a known APEX1 inhibitor) showed a KD of 8.921 × 10−5 mol/L

• Co-immunoprecipitation studies:

  • Assess how vitexin affects the interaction between APEX1 and p300

  • Determine if vitexin disrupts APEX1 acetylation by preventing p300 binding

• Acetylation and nuclear translocation assays:

  • Use Acetyl-APEX1 (K6) Antibody to monitor changes in acetylation levels following vitexin treatment

  • Combine with subcellular fractionation or immunofluorescence to assess effects on nuclear translocation

What are the considerations for developing new monoclonal antibodies against acetylated APEX1?

Based on the experiences documented in developing monoclonal antibodies against acetylated APEX1, researchers should consider:

• Immunogen design:

  • Use peptide mixtures containing all combinations of single or multi-acetylated variants

  • For APEX1, the unstructured N-terminal domain (residues 24-39) which is acetylated on Lys27, Lys31, Lys32, and Lys35 has been used successfully

• Screening strategy:

  • Implement targeted screening to identify clones that bind specifically to acetylated variants

  • Test against both acetylated and non-acetylated peptides/proteins to confirm specificity

  • Assess cross-reactivity with unrelated acetylated peptides and proteins

• Affinity characterization:

  • Measure binding to purified mono-acetylated peptides

  • Determine affinity constants (KD) for each interaction

  • High-affinity antibodies typically show KD values in the picomolar range

• Specificity limitations:

  • Even well-developed antibodies may not be sufficiently specific to discriminate between differently acetylated forms of the peptide/protein

  • Despite this limitation, these antibodies can still enable sensitive and selective detection of acetylated APEX1 in cells and tissues

• Validation in biological systems:

  • Test antibody performance in cell lines treated with deacetylase inhibitors

  • Validate recognition in tissue samples from relevant disease models

  • Use proximity ligation assays to confirm specific detection of acetylated epitopes

What are the optimal conditions for immunoprecipitation using Acetyl-APEX1 (K6) Antibody?

For successful immunoprecipitation of acetylated APEX1, researchers should consider these technical parameters:

• Lysis buffer composition:

  • Include deacetylase inhibitors (e.g., TSA, nicotinamide) to preserve acetylation status

  • Use mild detergents that preserve protein-protein interactions

  • Add protease inhibitors to prevent degradation of APEX1

• Antibody amount and incubation conditions:

  • Typically use 1-5 μg of Acetyl-APEX1 (K6) Antibody per sample

  • Incubate overnight at 4°C with gentle rotation to maximize antigen capture

  • Consider pre-clearing lysates with protein A/G beads to reduce non-specific binding

• Washing conditions:

  • Use stringent washing to eliminate non-specific interactions

  • Maintain cold temperatures throughout to preserve protein integrity

  • Include deacetylase inhibitors in wash buffers

• Elution and detection:

  • Elute with sample buffer containing SDS for complete protein recovery

  • Use a pan-APEX1 antibody for detection to confirm successful immunoprecipitation

  • Consider complementary approaches like mass spectrometry to validate acetylation sites

How can researchers optimize immunohistochemistry protocols for detecting acetylated APEX1 in tissue samples?

When adapting Acetyl-APEX1 (K6) Antibody for tissue staining, consider these optimization strategies:

• Tissue fixation and processing:

  • Formalin fixation may mask acetylation-specific epitopes

  • Consider antigen retrieval methods specific for acetylated proteins

  • Fresh frozen sections may better preserve post-translational modifications

• Blocking conditions:

  • Use BSA or normal serum from the same species as the secondary antibody

  • Consider adding non-specific IgG to reduce background

  • Optimize blocking time to balance background reduction and signal preservation

• Antibody dilution optimization:

  • Start with manufacturer's recommended dilution range (e.g., 1:20-1:200 for IHC)

  • Perform a dilution series to determine optimal signal-to-noise ratio

  • Consider extended incubation times at lower antibody concentrations

• Signal detection systems:

  • Amplification systems may be necessary for detecting low abundance acetylated proteins

  • Consider tyramide signal amplification for enhanced sensitivity

  • Fluorescent detection allows for co-localization studies with other markers

• Validation controls:

  • Include tissue from models with known APEX1 acetylation status

  • Consider sequential staining with pan-APEX1 antibody for localization comparison

  • Use peptide competition controls to verify specificity

The antibody has been successfully used in tissue slices from both breast cancers and from patients affected by idiopathic dilated cardiomyopathy, demonstrating its utility in pathological tissue samples .

What troubleshooting approaches are recommended when working with Acetyl-APEX1 (K6) Antibody?

Common challenges and their solutions when working with Acetyl-APEX1 (K6) Antibody include:

• Weak or absent signal:

  • Treat samples with deacetylase inhibitors to increase acetylation levels

  • Verify total APEX1 expression using a pan-APEX1 antibody

  • Check antibody storage conditions (avoid repeated freeze-thaw cycles)

  • Optimize protein extraction methods to preserve acetylation

• High background:

  • Increase washing steps and duration

  • Optimize blocking conditions

  • Reduce primary antibody concentration

  • Consider more specific secondary antibodies

• Non-specific bands in Western blotting:

  • Use gradient gels for better separation

  • Optimize protein loading amount

  • Include peptide competition controls

  • Consider pre-adsorption of antibody with non-specific proteins

• Inconsistent results between experiments:

  • Standardize cell culture conditions that may affect acetylation status

  • Use internal controls for normalization

  • Prepare fresh working solutions of deacetylase inhibitors

  • Standardize the timing between treatment and sample collection

• Poor reproducibility in tissue staining:

  • Standardize tissue processing protocols

  • Optimize antigen retrieval methods

  • Use automated staining platforms if available

  • Include positive control tissues in each experiment

How can Acetyl-APEX1 (K6) Antibody contribute to atherosclerosis research?

Acetyl-APEX1 (K6) Antibody offers valuable insights into atherosclerosis pathogenesis and potential therapeutic approaches:

• Flow-dependent endothelial dysfunction:

  • Disturbed flow at atheroprone sites induces APEX1 acetylation and nuclear translocation

  • The antibody can detect these changes in cultured endothelial cells and tissue sections

  • Enables monitoring of endothelial responses to atherogenic stimuli

• Mechanistic studies of inflammation:

  • Acetylated APEX1 mediates flow-induced endothelial proinflammatory responses

  • The antibody can help track activation of NF-κB signaling downstream of APEX1 acetylation

  • Allows quantification of endothelial inflammation markers in relation to APEX1 acetylation

• Therapeutic target validation:

  • Depletion of endothelial Apex1 in mice ameliorated atherogenesis

  • The antibody can assess the efficacy of compounds targeting APEX1 acetylation

  • Vitexin inhibits APEX1 activation, providing a model for therapeutic development

• Translational research applications:

  • Monitor APEX1 acetylation status in human atherosclerotic plaque samples

  • Correlate acetylation levels with disease progression

  • Evaluate efficacy of potential therapeutic interventions in preclinical models

What is the potential role of APEX1 acetylation in cancer biology?

APEX1 acetylation has important implications in cancer biology that can be investigated using Acetyl-APEX1 (K6) Antibody:

• Nuclear accumulation in cancer cells:

  • Exclusive nuclear accumulation of acetylated APEX1 has been observed in lung adenocarcinoma cells

  • The antibody can detect differences in subcellular localization between normal and cancer cells

  • May serve as a potential biomarker for certain cancer types

• DNA repair mechanisms:

  • APEX1 plays crucial roles in base excision repair

  • Acetylation modulates this function, potentially affecting genomic stability in cancer cells

  • The antibody can help correlate acetylation status with DNA repair efficiency

• Transcriptional regulation:

  • Acetylated APEX1 may differentially regulate transcription factors in cancer cells

  • The antibody can be used in chromatin immunoprecipitation experiments to identify target genes

  • Helps understand the contribution of APEX1 to cancer cell transcriptional programs

• Therapeutic response prediction:

  • APEX1 acetylation status may affect sensitivity to certain chemotherapeutics

  • The antibody can monitor changes in acetylation following treatment

  • Potential predictor of treatment response in personalized medicine approaches

The antibody has been successfully used in breast cancer tissue samples, demonstrating its utility in cancer research applications .

What emerging technologies could enhance the study of APEX1 acetylation?

Several cutting-edge approaches could advance our understanding of APEX1 acetylation dynamics:

• Mass spectrometry-based acetylomics:

  • Quantitative MS approaches to precisely map all acetylation sites on APEX1

  • Determine stoichiometry of different acetylated forms under various conditions

  • Correlate with antibody-based detection methods for validation

• CRISPR-mediated acetylation site mutations:

  • Generate knock-in models with lysine-to-arginine mutations at specific sites

  • Create cells/animals expressing acetylation-mimetic mutations

  • Determine the specific contribution of K6 acetylation versus other sites

• Live-cell imaging of acetylation dynamics:

  • Develop biosensors for real-time monitoring of APEX1 acetylation

  • Combine with microfluidic systems to study flow-dependent effects

  • Track nuclear-cytoplasmic shuttling in response to various stimuli

• Single-cell acetylation analysis:

  • Adapt antibody-based detection for single-cell proteomics

  • Determine cell-to-cell variation in APEX1 acetylation within tissues

  • Correlate with cell state and disease progression

• High-throughput screening for modulators of APEX1 acetylation:

  • Use acetylation-specific antibodies to identify compounds that modify APEX1 acetylation

  • Screen for inhibitors of p300-APEX1 interaction

  • Develop therapeutic approaches targeting pathological APEX1 acetylation

How might the study of APEX1 acetylation contribute to precision medicine approaches?

The study of APEX1 acetylation has potential implications for personalized therapeutic strategies:

• Biomarker development:

  • Acetylated APEX1 levels as predictive or prognostic biomarkers

  • Use Acetyl-APEX1 (K6) Antibody in liquid biopsies or tissue samples

  • Stratify patients based on APEX1 acetylation profiles

• Targeted therapeutic approaches:

  • Develop compounds that specifically inhibit APEX1 acetylation

  • Identify patient populations most likely to benefit from APEX1-targeted therapies

  • Monitor treatment efficacy using acetylation-specific antibodies

• Combination therapy strategies:

  • Determine how APEX1 acetylation status affects response to standard therapies

  • Design rational drug combinations targeting APEX1 and related pathways

  • Personalize treatment regimens based on individual APEX1 acetylation profiles

• Disease monitoring and prevention:

  • Track APEX1 acetylation in high-risk individuals (e.g., for atherosclerosis)

  • Develop preventive interventions targeting early changes in APEX1 acetylation

  • Use dietary components like vitexin that modulate APEX1 function